Evaluation of flavoglaucin, its derivatives and pyranonigrins produced by molds used in fermented foods for inhibiting tumor promotion

Bioscience, Biotechnology and Biochemistry

Volumn 74, Issue 5, 2010, Pages 1120-1122

  Miyake, Yoshiaki ^a   Ito, Chihiro ^b   Tokuda, Harukuni ^c   Osawa, Toshihiko ^d   Itoigawa, Masataka ^a  

^a TOKAI GAKUEN UNIVERSITY   (Japan)

^b MEIJO UNIVERSITY   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

^d NAGOYA UNIVERSITY   (Japan)

Author keywords

Antitumor promoter; Epstein Barr virus activation; Flavoglaucin; Mold; Two stage skin carcinogenesis

Indexed keywords

ANTI-TUMORS; EPSTEIN-BARR VIRUS; EPSTEIN-BARR VIRUS ACTIVATION; SKIN CARCINOGENESIS; TWO STAGE;

PATHOLOGY; TUMORS; VIRUSES;

MOLDS;

ANTIOXIDANT; FLAVOGLAUCIN; GENTISIC ACID; PYRONE DERIVATIVE; VIRUS ANTIGEN;

ANIMAL; ARTICLE; CHEMISTRY; DRUG EFFECT; EPSTEIN BARR VIRUS; FERMENTATION; FOOD CONTROL; FUNGUS; HUMAN; IC 50; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MOUSE; PATHOLOGY; SKIN TUMOR; TUMOR CELL LINE; VIROLOGY;

ANIMALS; ANTIGENS, VIRAL; ANTIOXIDANTS; CELL LINE, TUMOR; FERMENTATION; FOOD MICROBIOLOGY; FUNGI; GENTISATES; HERPESVIRUS 4, HUMAN; HUMANS; INHIBITORY CONCENTRATION 50; MICE; PYRONES; SKIN NEOPLASMS;

HUMAN HERPESVIRUS 4;

EID: 77955360659     PISSN: 09168451     EISSN: 13476947     Source Type: Journal    
DOI: 10.1271/bbb.90955     Document Type: Article

References (16)

1. Hennings H, Glick AB, Greenhalgh DL, Strickland JE, Tennenbaum T, and Yuspa SH, Proc. Soc. Exp. Biol. Med., 202, 1-18 (1993).
2. Wattenberg LW, Cancer Res., 53, 5890-5896 (1993).
3. Tokuda H, Ohigashi H, Koshimizu K, and Ito Y, Cancer Lett., 33, 279-283 (1986).
4. Hu CC, Hsiao CH, Huang SY, Fu SH, Lai CC, Hong TM, Chen HH, and Lu FJ, J. Agric. Food Chem., 52, 5735-5739 (2004).
5. Wang H, Jenner AM, Lee CY, Shui G, Tang SY, Whiteman M, Wenk MR, and Halliwell B, Free Radic. Res., 41, 479-488 (2007).
6. Miyake Y, Mochizuki M, Ito C, Itoigawa M, and Osawa T, Biosci. Biotechnol. Biochem., 72, 1580-1585 (2008).
7. Miyake Y, Ito C, Itoigawa M, and Osawa T, Biosci. Biotechnol. Biochem., 73, 1323-1327 (2009).
8. Itoigawa M, Ito C, Tokuda H, Enjo F, Nishino H, and Furukawa H, Cancer Lett., 214, 165-169 (2004).
9. Ito C, Itoigawa M, Kanematsu T, Imamura Y, Tokuda H, Nishino H, and Furukawa H, Eur. J. Med. Chem., 42, 902-909 (2007).
10. Iranshahi M, Kalategi F, Rezaee R, Shahverdi AR, Ito C, Furukawa H, Tokuda H, and Itoigawa M, Planta Med., 74, 147-150 (2008).
11. Itoigawa M, Ito C, Ju-ichi M, Nobukuni T, Ichiishi E, Tokuda H, Nishino H, and Furukawa H, Cancer Lett., 176, 25-29 (2002).
12. Ito C, Itoigawa M, Sato A, Hasan CM, Rashid MA, Tokuda H, Mukainaka T, Nishino H, and Furukawa H, J. Nat. Prod., 67, 1488-1491 (2004).
13. Yoshimi N, Wang A, Morishita Y, Tanaka T, Sugie S, Kawai K, Yamahara J, and Mori H, Jpn. J. Cancer Res., 83, 1273-1278 (1992).
14. Perchellet JP and Perchellet EM, Free Radic. Biol. Med., 7, 377-408 (1989).
15. Wei H and Frenkel K, Cancer Lett., 52, 2298-2303 (1992).
16. Nakamura Y, Ohto Y, Murakami A, Osawa T, and Ohigashi H, Jpn. J. Cancer Res., 89, 361-370 (1998).